Prodrugs pp 1207-1219 | Cite as

Case Study: Clindamycin 2-Phosphate, A Prodrug of Clindamycin

  • W. Morozowich
  • H. A. Karnes
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


The prodrug clindamycin 2-phosphate is rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. Clindamycin is an antibacterial agent used orally in treating gram-positive infections, anaerobic infections, and methicillin-resistant staphlococcal and streptococcal infections. Clindamycin 2-phosphate, unlike clindamycin, is highly water soluble and does not produce pain upon injection.


Benzyl Alcohol Benzoyl Peroxide Sodium Sulfosuccinate Vaginal Cream Lauroyl Sarcosinate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amr S, Brown MB, Martin GP, and Forbes B. Activation of Clindamycin Phosphate by Human Skin. J Appl Microbiol 2001; 90:550–554PubMedCrossRefGoogle Scholar
  2. Barza M, Goldstein JA, Kane A, Feingold DS, and Pochi PE. Systemic Absorption of Clindamycin Hydrochloride after Topical Application. J Acad Dermatol 1982; 7:208–214CrossRefGoogle Scholar
  3. Borglund E; Hagermark O, and Nord CE. Impact of Topical Clindamycin and Systemic Tetracycline on the Skin and Colon Microflora in Patients with Acne Vulgaris. Scand J Inf Dis Suppl 1984; 43:76–81Google Scholar
  4. Borin MT, Powley GW, Tackwell KR, and Batts DH. Absorption of Clindamycin after Intravaginal Application of Clindamycin Phosphate 2% Cream. J Antimicrob Chemother 1995; 35:833–841PubMedCrossRefGoogle Scholar
  5. Borin MT, Ryan KK, and Hopkins NK. Systemic Absorption of Clindamycin after Intravaginal Administration of Clindamycin Phosphate Ovule or Cream. J Clin Pharmacol 1999; 39:805–810PubMedCrossRefGoogle Scholar
  6. Brodasky TF, and Lewis C. In Vivo-In Vitro Comparison of the 2-and 3-Phosphate Esters of Clindamycin. J Antibiotics 1972; 25:230–238Google Scholar
  7. Chen S. Synthesis of Clindamycin Phosphate. Shanxi Yike Daxue Xuebao 2002; 33:116–117Google Scholar
  8. Eller MG, Smith RB, and Phillips JP. Absorption Kinetics of Topical Clindamycin Preparations. Biopharm Drug Dispos 1989; 10:505–512PubMedCrossRefGoogle Scholar
  9. Gray JE, Weaver RN, Moran J, and Feenstra ES. Parenteral Toxicity of Clindamycin 2-Phosphate in Laboratory Animals. Tox Appl Pharmacol 1974; 27:308–321CrossRefGoogle Scholar
  10. Guin JD, and Lummis WL. Comedonal Levels of Free Clindamycin Following Topical Treatment with a 1% Solution of Clindamycin Phosphate. J Am Acad Dermatol 1982; 7:265–268PubMedGoogle Scholar
  11. Karnes HA. Large Scale Synthesis of Phosphate Esters and Phosphonates. Oral Presentation, Newman Symposium, Ohio State University, April 6, 1978Google Scholar
  12. Kipp JE, and Hlavaty, JJ. Nonisothermal Stability Assessment of Stable Pharmaceuticals: Testing of A Clindamycin Phosphate Formulation. Pharm Res 1991; 8:570–575PubMedCrossRefGoogle Scholar
  13. Liu Hong-Min, Zhu Wei-Guo, Liu Zhen-Zhong, Li Xiao-Qiang, and Kang Jian-Xun. Study On The Synthetic Process of Clindamycin Phosphate Monitored by 31P NMR. Bopuxue Zazhi 2002; 19:181–186Google Scholar
  14. Matier WL, Woo C, and Lee YC. Preparation of Clindamycin 2-Phosphate Benzyl Ester. US Patent 4,849,515, 1989Google Scholar
  15. Meadowcroft AM, Diaz PR, and Latham GS. Clostridium Difficile Toxin-Induced Colitis after Use of Clindamycin Phosphate Vaginal Cream. Ann Pharmacother 1998; 32:309–311PubMedCrossRefGoogle Scholar
  16. Morozowich W, and Lamb DJ. Lincomycin 2-Phosphates, 7-Substituted Compounds and Salts Thereof. US Patent 3,487,068, Dec. 30, 1969Google Scholar
  17. Morozowich W, and Lamb DJ. Lincomycin 2-Phosphate Antibiotic Compositions and Process of Treatment. US Patent 3,509.256, April 28, 1970Google Scholar
  18. Morozowich W, Lamb DJ, DeHaan RM, and Gray JF. Clindamycin 2-Phosphate, an Injectable Derivative of Clindamycin with Improved Muscle Tolerance. J Pharm Sci 1970; p.63, Abstracts, APHA Acad. Pharm. Sci., 117 th Meeting Amer. Pharm. Assoc., April 12–17, Washington, D.C..Google Scholar
  19. Morozowich W, Lamb DJ, Karnes HA, Mackellar FA, Lewis C, Stern KF, and Rowe EL. Synthesis and Bioactivity of Lincomycin-2-Phosphate. J Pharm Sci 1969; 58:1485–1489PubMedCrossRefGoogle Scholar
  20. Munson JW, and Kubiak EJ. A High Performance Liquid Chromatographic Assay for Clindamycin Phosphate and its Principal Degradant Product In Bulk Drug Formulations. J Pharm Biomed Anal 1985; 3:523–533PubMedCrossRefGoogle Scholar
  21. Oesterling TO, and Rowe EL. Hydrolysis of Lincomycin-2-Phosphate and Clindamycin-2-Phosphate. J Pharm Sci 1970; 59:175–179PubMedCrossRefGoogle Scholar
  22. Nahata MC, Morosco RS, and Hipple TF. Stability of Cimetidine Hydrochloride and of Clindamycin Phosphate in Water for Injection Stored in Glass Vials at Two Temperatures. Am J Hosp Pharm. 1993; 50:2559–2561PubMedGoogle Scholar
  23. Pena LE. Topical Pharmaceutical Compositions. WO Patent, WO9407478, The Upjohn Co., Apr. 14, 1994Google Scholar
  24. Pena LE, Bowman PB, Chao RS, Shih-Liang R, Pesheck CV. U.S. Patent 6,495,157 B1, Intravaginal Clindamycin Ovule Composition, Pharmacia and Upjohn Co., Dec. 17, 2002Google Scholar
  25. PDR, Physicians Desk Reference, 59th Edition, 2005, Clindamycin 2-Phosphate, Montvale NJ: Thomson PDR; 2005:123–124Google Scholar
  26. Resman A, Jelen-Zmitek A, Jereb M, Kotnik S, Kovacic M, Lazarevski K, and Zmitek J. Solubility Dependence of Selected Active Substances. Acta Pharm 1996; 46:137–145Google Scholar
  27. Riebe KW, and Oesterling TO. Parenteral Development of Clindamycin-2-Phosphate. Bull Parent Drug Assoc 1972; 26:139–146Google Scholar
  28. Smith RB, and Phillips JP. Evaluation of Cleocin HCl and Cleocin Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982. This reference is provided in the PDR entry for Cleocin® Phosphate Injection, USPGoogle Scholar
  29. Tan JK. Clindoxyl Gel for the Treatment of Acne Vulgaris. Skin Therapy Lett 2002; 7:1–2PubMedGoogle Scholar
  30. Tobkes M, Diaz S, and Krishnan L. Preparation of Clindamycin Phosphate. US Patent 5,182,374, Jan. 26, 1993Google Scholar
  31. Ye, YR, Bektic E, Buchta R, Houlden R, and Hunt B. Simultaneous Determination of Tretinoin and Clindamycin Phosphate and their Degradation Products in Topical Formulations by Reverse Phase HPLC. J Separation Sci 2004; 27:71–77CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • W. Morozowich
    • 1
  • H. A. Karnes
    • 2
  1. 1.Pfizer Inc.Kalamazoo
  2. 2.Bridge Organic ChemicalsVicksburg

Personalised recommendations